GOG-0265 Phase 2 trial

May 31, 2017May 31, 2017

New Study to Assess ADXS-DUAL, Opdivo Immunotherapy Combo in Metastatic Cervical Cancer

News

Advaxis and Bristol-Myers Squibb have entered a clinical collaboration to evaluate the second generation of axalimogene filolisbac, called ADXS-DUAL, in combination with Opdivo (nivolumab) in women with metastatic cervical cancer. ... Read more

March 17, 2017March 17, 2017

Advaxis Vaccine Generates Unprecedented Survival Rates in Metastatic Cervical Cancer

News

Advaxis‘ cancer vaccine, axalimogene filolisbac, significantly increased cervical cancer patients’ 12-month survival rate, according to a clinical trial. Patients with persistent or recurrent metastatic carcinoma of the cervix (PRmCC) who took the ... Read more